Dynamic Dashboard - Categories and Definitions

The definitions are intended to be applicable across the different One Health sectors.

R&D in scope	 Basic and applied research on AMR that covers all One Health sectors (human, animal, plant and environment). The infectious agents in scope are provided In the Dynamic Dashboard Library. The activities could include but are not limited to: All types of product-oriented and product-based R&D, including research, discovery, development (including field trials), first registration and post registration studies for therapeutics, preventives, promotants and diagnostics Basic research that improves understanding of the pathogen, virulence, transmission, impact of external factors and roles and interaction of different One Health sectors and is not necessarily geared towards a specific product, policies or operational processes Operational/implementation research such as exploring improvements to surveillance, access to and optimal use of products, epidemiology-related studies, digital products, infection prevention and control and disease management programs Research of new or existing medical interventions Research to inform policy or regulation development or revision Relevant research training (such as support for PhDs & post-docs) and network establishment (capacity building) Research on breeding genetic variances targeting AMR Research that leads to reduced antibiotic/antimicrobial use (agent not specified)
Exclusion	Information will not be collected for projects or investments on:
criteria	 Research on non-communicable diseases, such as obesity, autoimmune diseases, cancer, allergies, in the context of the use of viral vectors
	R&D on virally caused cancers, reactivated viral infections in immunocompromised
	individuals such cytomegalovirus or progressive multifocal leukoencephalopathy

- Grants solely for symposia or meetings or travel
- Funding for buildings / capital investments
- Training and professorships where there is not a strong focus on AMR R&D
- Research into insect vector control, biocontrol of insects and insects as pests in general

Research Area

Basic research	Research that addresses fundamental aspects of a concept or phenomenon and aims at increasing scientific knowledge, understanding about the disease, immune response, processes or pathogen
	but is not yet directed towards a specific product, policies, or operational processes and
	corresponds to Technology Readiness Levels (TRL, see Annex for definition) 1-3.
	This research area includes projects that address both 'fundamental' aspects but also are moving
	'towards a product' and could include but are not limited to:
	Fundamental - no clear path to product development (TLR 1-2)
	Research into the development and mechanisms of persistence, transmission, virulence,
	immunology, biology and pathology; genetics (including genetically resistant animals and
	plants); role of the microbiome in maintenance of health; role of antibiotics in growth
	promotion; epidemiology and burden; and the interaction between One Health sectors
	• Fundamental understanding of biological processes or chemistry involved in the synthesis
	of compounds, including adjuvants and antigens
	Towards a Product - has the potential to become a product (TLR 3)
	 Search for a potential therapeutic, preventive, promotant or diagnostic target
	Early research for the development of imaging or detection technologies/assays
	• Development of technologies and in silico/in vitro/in vivo models that assist with the
	design and testing of e.g. drugs and vaccines such as tissue culture and animal models (e.g.
	mouse models for sepsis, challenge models)
	• Identification of mode of action of putative new products targeting the pathogen, host
	and/or the microbiome

	• "Platform technologies" e.g. for vaccines that broadly refer to a system that uses the same			
	basic components as a backbone, but can be adapted for use against different pathogens			
	by inserting new sequences (which then would become product-specific)			
Therapeutics	Any product-specific R&D designed for the treatment of infection with an antimicrobial across all			
includes	product-specific R&D stages such as screening of compounds/antigens, early stages of optimising a			
therapeutics and	hit or work to better understand a target to post registration studies. This could include but is not			
treatment	 Improvement of current antimicrobials, treatment regiments and therapies 			
	 Improvement of current antimicrobials, treatment regiments and therapies Investigation of combination therapies 			
	Dose optimisation studies Investigation of old or off market antimicrobials for optimisation or new targets			
	 Investigation of old or off market antimicrobials for optimisation or new targets Development of new antimicrobials and therapeutic alternatives to 'traditional' 			
	antimicrobials, including but not limited to small molecules, natural products, antibodies,			
	vaccines, probiotics and faecal transplant therapy, bacteriophages, antimicrobial peptides,			
	lysins, antitoxins and immune modulators			
	 Drug quality (including fake or sub-standard drugs) and properties such as oral 			
	bioavailability, long half-life, etc that are secondary to activity but can be essential to			
	market viability			
	Characterise a target for which some evidence of its usefulness is already available			
	Combining identification of target and other aspects such as screening/optimising of			
	compounds			
	In plants, this includes treatment of diseases			
Vaccines	Any product-specific R&D designed to prevent systemic disease (no symptoms, could be both sick			
	and healthy subjects).			
	Vaccines are defined as a product (usually a biological preparation or substance) that stimulates the			
	adaptive immune system to develop long-lasting protective immunity against antigens from			
	pathogens and is administered primarily to prevent disease. This is achieved, in general, through the			
	generation of antigen-specific memory T and B cells (adaptive/acquired immune system).			
	Research that addresses challenges in developing vaccines, e.g. identification of protective			
	antigens, defining correlates of protection, understanding most effective antigen delivery			
	methods and stimulating long-term protective immune responses			
	Identification of vaccine candidate(s): Screening of potential natural or synthetic antigens			
	and other vaccine components (e.g. adjuvants) in a pathogen/disease-specific context and			
	may include e.g. protein/peptide/epitope libraries, antigen-expressing vectors, substances			
	derived from pathogens, weakened pathogens or their toxins, serological activity			
	(neutralising and non-neutralising)			
	 Studies conducted to assess vaccine candidate for safety and efficacy (e.g. in tissue-culture or cell-culture and animal testing and clinical trials) 			
Preventives -	Any product-specific R&D designed to prevent systemic disease (no symptoms, could be both sick			
Other	and healthy subjects).			
other	Preventives – Other are defined as a product (often a drug) that prevents disease through other			
	means than vaccination and by itself does not generate an antigen-specific memory immune			
	response. These are usually introduced into the host by e.g. injection, taken orally or as food/feed			
	as opposed to other products that are applied topically.			
	 Prophylactics – medication/treatment to prevent disease from occurring- e.g. 			
	administration of antimicrobial with appropriate therapeutic dose for limited and disease			
	appropriate duration in healthy subjects at risk of specific infection or where			
	infection/disease is likely to occur			
	Immune modulators – activate, boost or restore normal immune function independent			
	on the pathogen causing infection (not antigen-specific); These include cytokines,			
	lipopolysaccharides, short segments of bacterial DNA that also stimulate innate immune			
	responses (i.e. CpGs), antibodies, and certain plant materials			
	• Trait-selective breeding of animals/plants resistant to AMR infections, e.g. genome editing			
	technologies for the generation of genome editing animals/plants			
	Other disease prevention products, such as antibiofilm enzymes			
Diagnostics	Any product-specific R&D aimed at the development or improvement of detection, screening or			
includes	diagnosis. This could include but is not limited to:			
detection,	 Identification of causative agent (including distinguishing between viral and bacterial) and identification of registrance (including registrance profiles) including suscentibility testing 			
	identification of resistance (including resistance profiles), including susceptibility testing			

[
screening and	 Development of diagnostic or prognostic tests and devices for clinical use, and use in the field (a.g. animal form activities)
diagnostics	field (e.g. animal farm-settings)
	• Tests and screening tools for population-based, epidemiological studies and surveillance routines aiming at the identification of determinants that are involved in the cause, risk or
	development of AMR
	 Development of companion diagnostics – provide information for the safe and effective
	use of a corresponding drug or biological product
	• Development of tests or detection tools including machine learning predictions to identify
	infected individuals or status of infections with AMR-relevant agent(s) within a herd/flock)
	or environment
	 Diagnostic tools in support of trait-selective breeding of animals/plants, e.g. genotyping
	technologies to improve disease resistance (e.g. SNPs)
Promotants	Any product-specific R&D designed to improve or maintain health/welfare and increase productivity
	and/or growth in the absence of disease/infection. They are usually provided as food/feed
	additives. This could include but is not limited to:
	 Non-medically important antimicrobials at sub- or non-therapeutic doses used for an on- going duration
	 Probiotics - live cultures of microorganisms (e.g., yeast, algae, fungi and bacteria) added to
	the diet to improve the balance of microbial communities in the gastrointestinal tract
	 Prebiotics - organic compounds such as certain sugars that, when added to the diet, are
	indigestible but are broken down by certain beneficial microorganisms in the gut, which
	selectively stimulates these and other microorganisms' growth
	Antimicrobial peptides - short molecules with antibacterial properties that are toxic to
	certain bacteria
	Phytochemicals - plant-derived compounds, such as essential oils or tannins that may have
	antibacterial and growth promoting effects
	 Organic acids, enzymes and other alternatives, such as heavy metals (zinc, copper) and clay
Other products	minerals Any product-specific R&D that does not fit under therapeutics, preventives, promotants or
Other products	diagnostics and are usually for external/topical application. It does not include devices that are part
	of delivery systems for therapeutics, vaccines or diagnostics. This could include but is not limited to:
	• Biocides - used as antiseptics and disinfectants – chemicals and biological agents used for
	the expressed purpose to control, deter, inhibit or kill harmful microorganisms
	Biofilm-related products (material, devices, particles, etc) that prevent, prohibit or
	interfere with biofilms
	Other products like medical devices, wound healing products/dressing, anti-adhesions
	• Technologies to improve and monitor health, production and welfare in animals such as
	sensors/devices (via microbiome/weight gain, etc) at individual and herd/flock level
Operational	(reduction of AMU) Operational and implementation research that aids in decision making and management strategies
Operational includes	(at the organisational and local levels) and could include but is not limited to:
operational and	Infection prevention and control (IPC): Management and interventions aimed at
implementation	optimizing clinical, veterinary or farming practice related to: disinfection, sterilisation and
,	disease management programmes (e.g. biosecurity, husbandry methods, use of
	vaccination, health management) and evidence-based guidelines/policies of IPC
	programmes
	Optimal use / Stewardship: Research and studies to optimise the uptake and use of
	products (antimicrobials, diagnostics and vaccines and other technologies) with the aim of
	reducing the emergence or rate of development of resistance and/or the need to consume
	antibiotics, and normally does not impact product-specific label (see registration and implementation). Includes trials which compare agents against each other to inform clinical
	implementation). Includes trials which compare agents against each other to inform clinical practice and guideline development
	Surveillance: Population-level analysis of disease surveillance or monitoring, antimicrobial
	consumption/usage and resistance trends/development/susceptibility; includes specific
	informatics tool for collection, management and analysis of AMR testing data
	Epidemiology: Studies that analyse determinants of health and disease conditions in
	defined populations, specifically how, who, when, and where they occur. Major study
	 Access and Availability: Work that aims to improve the access and availability of AMR- and infection-reducing technologies Surveillance: Population-level analysis of disease surveillance or monitoring, antimicrobial consumption/usage and resistance trends/development/susceptibility; includes specific informatics tool for collection, management and analysis of AMR testing data Epidemiology: Studies that analyse determinants of health and disease conditions in

	 areas include disease causation, transmission, outbreak investigation, disease surveillance, environmental epidemiology, occupational epidemiology, screening, biomonitoring, and comparisons of treatment effects such as in clinical trials Social Science: Research to inform behavioural change among humans (individuals, groups such as farmers, organisations/companies,) or in relation to animals, economic analysis to inform and quantify challenges or costs-solutions. Impacts of external factors (such as assessments of the contribution of pollution or contamination); the environmental impact of new antimicrobials; digital products Other: Research that comprises <i>in silico</i> modelling (e.g. for optimisation of processes within wastewater treatment plants) 			
Capacity	Efforts aiming to improve the human or infrastructural resource capacity to address the challenges			
building	of AMR. May include but is not be limited to: laboratory capacity, staff training, network formation			
includes capacity	(for knowledge sharing only), infrastructural or process improvements for example clinical trial			
building and	conduct – that goes beyond a single product.			
infrastructure				
Policy	 Research or investments that will inform the development of, review or revision of policies and regulations (national and international). This could include but is not limited to: Relevant research, not listed above, with an objective of informing or proposing concrete changes to policy of influencing stakeholder-action in the field of AMR Impact of care services such as research into how social factors, financing systems, structures and processes, technologies and behaviours affect access to care, the effectiveness of care, and development and evaluation of interventions to improve services Economic impact, cost benefit analysis, economic models and incentives and market analysis Health technology assessments Supporting evidence of intervention into national health programmes (economic impact) 			

Product-specific Definitions

· · · · · · · · · · · · · · · · · · ·				
Discovery	 The discovery and preclinical testing of innovative methods, processes, active ingredients, antigens, adjuvants, delivery vehicles/methods, diagnostics and corresponds to 'Technology Readiness Levels' 4-5. Several in vitro and in vivo methods are applied in order to assess biological activity, immunogenicity, efficacy and safety (toxicological studies) of potential candidates. The preclinical phase concludes with submission of an IND (Investigational New Drug) application with FDA-US or CTA (Clinical Trial Application) EMA-EU by submitting the IMPD (Investigational Medicinal Product Dossier). For therapeutics and drug preventives this includes target validation, the hit discovery process (hit identification, hit to lead, lead identification and optimisation) For preventative biologics such as vaccines this includes identification, selection and improvement/characterisation of vaccine components (antigen, adjuvant, carrier/delivery system, etc) that have the ability to induce immunogenicity (induction of cellular and 			
	system, etc) that have the ability to induce immunogenicity (induction of cellular and humoral immune response/adaptive immune responses). This may include testing of			
	serum in order to identify antigens/immunogens (samples from exposed individuals for			
	testing immunogenicity), testing for ability to induce protective immune responses (e.g. by challenge with pathogen in animal or human models)			
	For diagnostics, this includes concept, feasibility, prototype development, and			
	development of technical specifications			
	 In Animal Health, includes market assessment to identify unmet animal health needs, 			
	preclinical/feasibility studies, including proof-of-concept safety and efficacy studies, and			
	are usually conducted in target species			
	 In plants, this includes treatment concepts and other control strategies 			
Development	The progression of selected candidates from discovery to commercialisation including investigating			
-	the efficacy and safety of the product in the field (e.g. clinical trials under GCP conditions),			
	reformulation and repurposing and validation of manufacturing processes. This stage concludes			
	with submission of an NDA (New Drug Application) or NADA (New Animal Drug Application) with			
	the FDA/CVM or appropriate applications/dossiers with agencies in other countries and			
	corresponds to 'Technology Readiness Levels' 6-8.			

	 In Human Health, for therapeutics and preventives this includes clinical trial Phase 1 to Phase 3, and trials that will lead to an expansion of the product label (additional indications) 		
	 In Animal Health, Target Animal Safety Studies (TASS) and Target Animal Effectiveness 		
	Studies (TAES) are conducted and include dose-finding and field trials (designed to mimic its 'everyday' use)		
	• For diagnostics this includes design lock, validation of manufacturing process, validation of		
	accuracy and analytical performance in (clinical) trials, validation of performance and		
	operational characteristics during uncontrolled routine use in programmatic settings		
Approval and	Refers to the phase following first market authorisation (early-commercialisation) for a specific		
post-approval	product and corresponds to 'Technology Readiness Levels' 9. This could include but is not limited to:		
	 Filing in other, subsequent, legal jurisdictions (countries) 		
	• All subsequent research and monitoring that is a requirement by regulators (post-approval requirements or post-authorisation obligations), such as: paediatric investigation plans		
	(PIPs), pharmacovigilance (phase 4) etc		
	Research into product optimisation (such as bioavailability, formulations)		
	Clinical studies which help inform how a product should be used in a clinical setting to		
	inform among others product formulary inclusion, guideline incorporation, value-		
	assessment and payor decisions		

Funders/Investors

In general, **public funding** is sponsored by a government agency or other publicly-recognized organization, whereas **private funds** are donated mainly through private corporations or philanthropic efforts by a private organization or individual or are invested directly by the private legal entity.

Public – government	Public funding provided at any level of government. This also includes agencies if located within a ministry/department portfolio.			
Public – other	 Research councils: separate legal entities and politically independent from government (they may still be answerable) Public universities: state or government owned or receive significant public funds through government 			
Private – for profit	 Pharmaceutical and Biotechnology companies, other relevant entities: entities that research, develop, manufacture, market, distribute, import, offers for sale or sell pharmaceutical products or other products relevant to AMR. Small and medium-sized enterprises (SME): non-subsidiary, independent firms with fewer than 250 employees and with annual turnover under EUR 50 million / US \$ 55 million. 			
Private – not for profit	Foundations: independent legal entities set up for charitable purpose and are funded by an endowment, an individual, a family or business (corporation). They are often controlled by an independent Board.			
Multilateral organisations	Refers to an alliance of multiple countries pursuing a common goal and deal with issues that are global priorities. Examples include the UN organisations such as WHO, FAO and UNEP and others such as OIE. World Bank, G20, EIB and GAVI.			
Funding distributor	such as OIE, World Bank, G20, EIB and GAVI. In the AMR field funders support organisations that in turn fund external projects or invest in own activities. Both the upstream grants and the downstream investments will be captured. To avoid double-counting, the notion of funding distributor has been introduced in the data-base. Projects/investments made by a funding distributor are referenced to said funding distributor. This then also allows to trace back the funding flow to where the original investment came from. Examples of such funding distributors are CARB-X and GARDP. The former is a funding organisation, the latter a product-development-partnership investing mostly in its own projects. Funding arrangements, where different funders work together through a "virtual pool of funding" are not considered a funding distributor, as the individual funded projects are each recorded only once from the respective funders.			

Type of Research Organisations

A research organisation is an entity, irrespective of its legal status (organised under public or private law) or way of financing, whose primary goal is to independently conduct fundamental or applied research (industrial research and experimental development).

Industry	Refers to a business entity with the aim of gaining profit.	
SME	Belonging to industry but defined and recorded separately are 'small and medium-sized enterprises (SME)': non-subsidiary, independent firms with fewer than 250 employees and with annual turnover under EUR 50 million / US \$ 55 million	
Private research	Refers to a privately owned building or facility whose primary mission is to pursue research in a	
institution/facility	specific area and which is not a university. Examples include, Scripps Research, Broad Institute,	
	Salk Institute, J. Craig Venter Institute, La Jolla Institute for Immunology, and Cold Spring Harbor Laboratory.	
Public bodies	Refers to an organisation operated mainly by the government of one or multiple countries/territories, which is not a university or a public research institution/facility and includes international organisations. Examples include, Ministry, City, City Council, World Health Organization (WHO), Food and Agriculture Organization of the United Nations (FAO) and World Organisation for Animal Health (OIE).	
Public research	Refers to a publicly owned building or facility whose primary mission is to pursue research in a	
institution/facility	specific area and which is not a university. Examples include, National Center for Global Health and Medicine, Max Planck Society (MPG).	
University	Refers to a public or private educational institution where research takes place. Can grant degrees and includes faculties, departments and schools.	
Other	Used in cases where none of the previously mentioned types are suitable, such as non-profit organisation (NGO) and Civil Society Organisations. Examples include, The Global Fund to Fight AIDS, Tuberculosis and Malaria, GAVI, Doctors Without Borders.	

Diseases and Syndromes

Includes diseases and syndromes that affect humans and animal species.

Disease or	Bloodstream infections:
syndromes	The presence of viable bacteria or fungi in the bloodstream, demonstrated by positive
	blood culture(s).
	Bone and joint infections:
	Any infection of the bone or joints noting there may be some cross over with skin and soft
	tissue infection.
	Gastrointestinal tract infections:
	 Any infection (or intoxication or inflammation caused by an infectious agent) of the
	gastrointestinal including the oesophagus, stomach, small and large intestine and rectum and the accessory organs of digestion, the liver, gallbladder and pancreas.
	Infections in pregnancy, during childbirth or in the puerperium period:
	 Includes both maternal and obstetric infections and infections during the first six weeks following birth.
	Nervous and sensory system infections:
	 Any infection of the nervous system (central and/or peripheral) or sensory organs such as
	ears, eyes and tongue. It excludes the skin (which is captured under skin and soft tissue
	infections) and the nose (which is captured under respiratory tract infection).
	Respiratory tract infections:
	 Any infection of the upper or lower respiratory tract including the nasal cavity, pharynx,
	larynx, trachea, and lungs.
	Sepsis (incl. Host response to infection):
	• An inflammatory immune response triggered by an infection and where host response to
	infection causes injury to tissues and organs.
	Sexually transmissible infections:

 Infections that are passed from one person to another through sexual contact. Noting that there may be cross over with other areas including UTIs, skin and soft tissue infection, infections in pregnancy, during childbirth or in the puerperium period, and gastrointestinal tract infections.
Skin and soft tissue infections:
• An infection of the layers of the skin and underlying soft tissues including subcutaneous tissue, muscles, tendons, ligaments, fascia, and fibrous tissue.
Urinary tract infections:
 An infection in any part of the urinary system including kidneys, ureters, bladder and urethra.
Lameness:
 Can be caused by a group of infections (most common bacterial) specific to the feet and involves damage to the skin and epidermis due to injury or prolonged moisture.
Mastitis:
Persistent, inflammatory reaction of the mammary gland and tissue (breast or udder) due
to microorganism infection (most common bacterial).

Sub-Categories for Sector – Animal

The definitions below include any animal and animal-derived components such as milk, meat, eggs, fur, leather and wool. Within each animal group all ages and gender are include. Animal-derived products for human consumption (food) follow the same categorization and are tagged as 'Food' accordingly. Farmed animal groups include livestock, poultry, aquaculture and insects and non-farmed animal groups include companion animals and wildlife.

Animal		no information regarding the animal group, name or species provided
Livestock		refers to any breed or population of animals kept by humans for a useful, commercial purpose and includes animals raised in an agriculture setting to produce labour and commodities such as meat, milk, fur, leather and wool
	Cattle	refers to any cattle (dairy, beef and meat), including cows, bulls, oxen or calves
	Small ruminants	refers to sheep (Ovis spp) and goats (Capra spp)
	Pig	refers to domesticated pigs (genus Sus), including terms e.g. swine, porcine, hogs, pork
	Livestock-Other Food	includes all other domesticated, farmed or captive wild animals (terrestrial) such as bovine (buffalo, bison, yak), Camelidae (camels, llamas, alpacas), Equidae (horses, donkey, mules/hinnies), lagomorphs (hares and rabbits), cervids
	Livestock-Other Non-Food	refers to all domesticated, farmed or captive wild animals (terrestrial) kept for fur and skin
	Not specified	refers to term 'livestock' without additional information regarding the animal group, name or species
Poultry		Domesticated or farmed birds, including backyard poultry, kept by humans for their eggs, meat or feathers
	Chicken	refers to chicken (<i>Gallus domesticus</i>), including hen, rooster/cock, chicks and terms such as broiler
	Other	includes e.g. turkey, quail, ostrich, pigeons, ducks, geese
	Not specified	refers to term 'poultry' without additional information regarding the animal group, name or species
Aquaculture		refers to farming of aquatic animals and implies some form of intervention in the rearing process to enhance production (e.g. feeding, regular stocking, protection from predators).
	Fish	refers to any fresh or saltwater species, most common farmed fish are in order carp, salmon, tilapia and catfish
	Other	includes species within e.g. crustaceans, Mollusca and amphibia and terms such as shellfish
	Not specified	refers to term 'aquaculture' without additional information regarding the animal group, name or species
Insects		refers to small hexapod invertebrates within the arthropod phylum and includes domesticated insects such as honeybee (genus Apis) and silkworm
Companion		refers to animals kept as pets, but can also be in a laboratory and medical/educational set-up and includes e.g. cats, dogs, ferrets, rodents. It can also include birds and reptiles (except if captured above)
Wildlife		refers to any feral animal, captive wild animal or wild animal (non-domesticated and non-farmed) that has a phenotype unaffected by human selection and lives independent of direct human supervision or control (exception zoo animals)

Sub-Categories for Sector – Plants

The definitions below include any plant and plant-derived components. If antimicrobial component is used in context of a harvested plant, then it follows the same categorization is tagged 'Food'.

Plant	Sub-Category	Definition	Species include but not limited
Cereals		refers to any grass cultivated for the edible components of its grain and includes true grains, whole grains and ancient grains.	wheat, rye, rice, maize (corn), barley, oats, ancient grains (e.g. farro, buckwheat, quino), sorghum, millet, also includes cereal grains without any information regarding group, name or species.
Сгор		refers to any cultivated plant that is grown on a large scale commercially without any information regarding the plant group, name or species (e.g. grains).	fibre crops (Cotton, hemp, flax, bamboo), industrial crops, animal feed (turnups, alphapha), plants used for beverages (coffee, teas)
Fruits		refers to the sweet and edible part of a plant that develops from the flower of the plant. It usually contains seeds or stones and can be eaten raw. Note that some plants that are botanical fruits but are often referred as vegetables are categorized as 'vegetable fruit'.	
	Berries	refers to any small fruit that can be eaten whole and do not have stones or pits, but may have pips or other small seeds. Note, the strict botanically definition is not applied and many fruits that are commonly known as berries but are botanically not berries are included. In contrast, many botanically true berries but commonly not known or referred to as berries are excluded.	strawberries, raspberries, blueberries, blackberries, currants, kiwis, grapes, watermelon, pineapple
	Citrus	refers to fruits from the genus of flowering trees and shrubs in the Rutaceae family.	orange, citron, lemon, lime, grapefruit, kumquat, mandarin, tangerine, pomelo, papeda
	Stone	refers to fruits with a pit or 'stone' inside that is encased in a fleshy outer area, also referred as drupe fruits. Includes prunus spp.	plums, cherries, nectarines, apricots, mangoes, lychees, dates, peaches, olives, coconuts, almonds, prunes, dates
	Not specified	refers to fruits where no additional information regarding the plant group, name or species is provided.	
	Other	refers to fruits where specific information is provided but not covered by any other fruit subcategory, such as pome fruits (e.g. apple, pear), simple fruits (e.g. banana),	banana, apples, pears, avocado
Oil Seeds		refers to grains grown primarily for the extraction of their edible oil and includes legumes mainly used for oil extraction (e.g. groundnuts/peanuts, cowpea).	sunflower, soybean, canola, rapeseed, sesame seeds, poppy seeds, pumpkin seeds, flaxseed, groundnuts/peanuts
Pulses/Beans		refers to the dry fruit or seed (pulse) of a plant harvested for consumption (food/feed). Excludes: legumes harvested green for food (e.g. green peas, green beans) which are classified as vegetable crops and legumes used mainly for oil extraction or used	beans (e.g. kidney, red, pinto, black, lima, broad, mung), peas (e.g. chick, black eyed, split), lentils

		exclusively for sowing purposes (e.g. seeds of clover and alfalfa).	
Tree Nuts		refers to the collective term used to describe nuts that grow on trees and may not all be botanically true nuts.	hazelnuts, chestnuts, walnuts, pecan nuts, cashew nuts, macadamia nuts, pistachio, pine nuts, almonds, coconuts
Vegetables		refers to the edible part of a plant (e.g. leaves, roots, flowers) but does not include the fruit or seed. Sub- categories are based on which part of plant vegetable comes from.	
	Fruit	refers to plants that botanically belong to fruits but are classified as vegetables based on culinary utility (cooked as vegetables and less sweet as fruits).	tomatoes, bell peppers, cucumbers, squashes (zucchini and pumpkins), eggplants, melons
	Leafy Greens	refers to the edible leaves of plants that are eaten as vegetables.	lettuce, spinach, cabbage, collards, parsley, kale, mustard greens, bok coy, watercress, sprouts
	Roots/Tubers	refers to the underground plant parts consumed as food (roots) and/or to the enlarged structures of some plants used as storage and consumed as food (tubers), includes bulbs such as onions, leeks	potatoes, cassava, dahlias, yam, beets, carrots, horseradish, parsnips, sweet potatoes, turnips, artichoke, ginger, bulb and stem vegetables (Garlic, onions), leeks
	Stems/Flowers	refers to flowering parts of vegetable (plants) that can be consumed.	broccoli, asparagus, celery, rhubarb, brussels sprouts, cauliflower
	Mushrooms	refers to fungi that are eaten as vegetables.	button white, portabello, shiitake
	Not specified	refers to any vegetable where no additional information regarding the plant group, name or species is provided.	
	Other	refers to vegetables where specific information regarding plant group, name or species is provided but not covered by any vegetable subcategory.	
Wild Plants		refers to native plants and trees and includes indigenous plants.	Ash trees, European conifer forests
Plant-Not-specified		refers to plants without any information regarding the plant group, name or species.	
Plant-Other		refers to any plant that does not fall in any other category with relevance to AMR e.g. plants used for medicinal purpose, Arabidopsis (model plant, weed)	medicinal plants/herbs, Arabidopsis, Food - Additives such as herbs (dry and fresh), spices, condiments.

Sub-Categories for Sector – Environment

The definitions below provide a broad coverage of the different components that encompass the 'environment', and were chosen to span the continuum of areas that are relevant to AMR R&D.

Environment	Sub-Category	Definition
Wastewater		refers to any water contaminated or compromised by human use and/or activities. It usually refers to effluent water and can include studies on waste water treatment and water systems
	Health facilities	refers to wastewater originating in facilities that provide healthcare, e.g. hospitals, healthcare centres, nursing homes, pharmacies and drug stores, medical laboratory and research
Agriculture		refers to wastewater originating from animal and plant production (agriculture), including drainage water.
	Aquaculture	refers to wastewater originating from farming of aquatic animals.
	Industrial	refers to wastewater (aqueous discard) resulting from an industrial manufacturing process, e.g. antimicrobial manufacturing
	Domestic	refers to wastewater produced by households and community of people and can include municipal wastewater (but excluding industrial wastewater).
	Not specified	refers to any type of wastewater where no additional information is provided
	Other	refers to any type of wastewater where specific information is provided but not covered by any wastewater subcategory, e.g. surface runoff water or stormwater, wastewater treatment plants
	Water-surface	refers to any body of water above ground, regardless if it is fresh or saltwater and includes streams, rivers, lakes, wetlands, reservoirs, creeks and oceans
Water	Water-Not Specified	refers to any type of water where no additional information is provided.
	Water-Other	refers to any type of water where specific information is provided but not covered by any water subcategory, such as drinking water, irrigation, recreational, reclaimed
Soil-Waste		refers to any soil contaminated or compromised by human use and/or activities
	Compost	refers to organic matter derived from plant origin and green manure
	Manure	refers to organic matter derived from animals and used as organic fertilizer in agriculture, mostly consists of animal faeces (including animal bedding such as straw)
	Sludge	refers to a substance between solid and liquid form derived from a range of industrial processes, (waste)water treatment or sanitation systems, can include slurry (similar to sludge just thinner)
	Not specified	refers to any soil-waste where no additional information is provided
	Other	refers to any other soil specified but not covered by any soil-waste category
Soil		refers to any type of soil where either no additional information is provided or specific information is provided, e.g. agriculture soil, forestry, cropland, pastureland, sediment, grassland
Air		refers to the gaseous substance surrounding the earth and may include dust
Environment-Not specified		refers to any type of environment where no additional information is provided
Environment-Other		refers to any types of environment where specific information is provided but not covered by any of the subcategories

ANNEX

Technology readiness level (TRL)

TRL 1 – basic principles observed

TRL 2 – technology concept formulated

TRL 3 – experimental proof of concept

TRL 4 – technology validated in lab

TRL 5 – technology validated in relevant environment (industrially relevant environment in the case of key enabling technologies)

TRL 6 – technology demonstrated in relevant environment (industrially relevant environment in the case of key enabling technologies)

TRL 7 – system prototype demonstration in operational environment

TRL 8 – system complete and qualified

TRL 9 – actual system proven in operational environment (competitive manufacturing in the case of key enabling technologies; or in space)